198 related articles for article (PubMed ID: 29192504)
1. Utility of Fecal Calprotectin in Evaluation of Chronic Gastrointestinal Symptoms in Primary Care.
Ramraj R; Garcia A; Mosen D; Waiwaiole L; Smith N
Clin Pediatr (Phila); 2018 Aug; 57(9):1058-1063. PubMed ID: 29192504
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.
Henderson P; Casey A; Lawrence SJ; Kennedy NA; Kingstone K; Rogers P; Gillett PM; Wilson DC
Am J Gastroenterol; 2012 Jun; 107(6):941-9. PubMed ID: 22370604
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.
Quail MA; Russell RK; Van Limbergen JE; Rogers P; Drummond HE; Wilson DC; Gillett PM
Inflamm Bowel Dis; 2009 May; 15(5):756-9. PubMed ID: 19107785
[TBL] [Abstract][Full Text] [Related]
6. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
Conroy S; Hale MF; Cross SS; Swallow K; Sidhu RH; Sargur R; Lobo AJ
J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
[TBL] [Abstract][Full Text] [Related]
7. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
Rokkas T; Portincasa P; Koutroubakis IE
J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
[TBL] [Abstract][Full Text] [Related]
9. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
10. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.
Kim ES; Tarassishin L; Eisele C; Barre A; Nair N; Rendon A; Hawkins K; Debebe A; White S; Thjømøe A; Mørk E; Bento-Miranda M; Panchal H; Agrawal M; Patel A; Chen CL; Kornbluth A; George J; Legnani P; Maser E; Loudon H; Mella MT; Stone J; Dubinsky M; Sabino J; Torres J; Colombel JF; Peter I; Hu J;
Gastroenterology; 2021 Mar; 160(4):1118-1130.e3. PubMed ID: 33307026
[TBL] [Abstract][Full Text] [Related]
12. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
13. [Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease].
Bonnín Tomàs A; Vila Vidal M; Rosell Camps A
Rev Esp Enferm Dig; 2007 Dec; 99(12):689-93. PubMed ID: 18290691
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
[TBL] [Abstract][Full Text] [Related]
15. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease.
Canani RB; de Horatio LT; Terrin G; Romano MT; Miele E; Staiano A; Rapacciuolo L; Polito G; Bisesti V; Manguso F; Vallone G; Sodano A; Troncone R
J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):9-15. PubMed ID: 16385247
[TBL] [Abstract][Full Text] [Related]
16. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
18. Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease.
Tandon P; Lee EY; Maxwell C; Hitz L; Ambrosio L; Dieleman L; Halloran B; Kroeker K; Huang VM
Dig Dis Sci; 2021 May; 66(5):1639-1649. PubMed ID: 32533542
[TBL] [Abstract][Full Text] [Related]
19. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.
Krzesiek E
Adv Clin Exp Med; 2015; 24(5):815-22. PubMed ID: 26768632
[TBL] [Abstract][Full Text] [Related]
20. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
Walker GJ; Moore L; Heerasing N; Hendy P; Perry MH; McDonald TJ; Debenham T; Bethune R; Bewshea C; Hyde C; Heap GA; Singh A; Calvert C; Kennedy NA; Goodhand JR; Ahmad T
Aliment Pharmacol Ther; 2018 Apr; 47(8):1103-1116. PubMed ID: 29508423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
